SELLAS Life Sciences Group, Inc. balance sheet SLS

Annual Quarterly

As of Jun 30, 2026, SELLAS Life Sciences Group, Inc. had total assets of $145.4 million and total liabilities of $7.7 million. Total assets were up 350.0% from a year earlier. Stockholders' equity was $137.7 million. It held $138.3 million in cash and investments against $737,000 of total debt, net cash of $137.6 million. The current ratio, current assets divided by current liabilities, was 18.83.

USD in millions, except ratios and per-share amounts. The percent under a figure is the change from the same quarter a year earlier.

Q2 FY2026
Jun 30, 2026
Q1 FY2026
Mar 31, 2026
Q4 FY2025
Dec 31, 2025
Q3 FY2025
Sep 30, 2025
Q2 FY2025
Jun 30, 2025
Q1 FY2025
Mar 31, 2025
Q4 FY2024
Dec 31, 2024
Q3 FY2024
Sep 30, 2024
Assets
Cash
138
+446.9%
107
+277.1%
72
+417.0%
44
+110.7%
25
+176.6%
28
+54.2%
14
+448.9%
21
+429.9%
Cash and investments
138
+446.9%
107
+277.1%
72
+417.0%
44
+110.7%
25
+176.6%
28
+54.2%
14
+448.9%
21
+429.9%
Total current assets
143
+383.9%
111
+247.7%
75
+360.7%
49
+104.1%
29
+139.4%
32
+48.7%
16
+414.7%
24
+361.9%
Goodwill
2
+0.0%
2
+0.0%
2
+0.0%
2
+0.0%
2
+0.0%
2
+0.0%
2
+0.0%
2
+0.0%
Total assets
145
+350.0%
114
+226.6%
78
+303.2%
52
+94.5%
32
+113.7%
35
+43.1%
19
+212.5%
27
+227.8%
Liabilities and equity
Accounts payable
3
-7.5%
4
-3.3%
3
-15.8%
2
-49.3%
3
-47.3%
4
-49.3%
4
-37.9%
5
+4.8%
Total current liabilities
8
+26.2%
6
-6.3%
7
-26.2%
6
-44.2%
6
-50.2%
7
-52.3%
10
-30.8%
11
-9.6%
Total liabilities
8
+25.5%
7
-6.0%
7
-25.0%
6
-44.2%
6
-49.6%
7
-51.2%
10
-29.8%
11
-10.9%
Stockholders' equity
138
+426.4%
107
+286.9%
71
+648.8%
46
+187.1%
26
+797.7%
28
+186.6%
9
+218.7%
16
+515.3%
Debt
Lease liabilities
1
+0.0%
1
+0.1%
1
+0.0%
1
+4.0%
1
+6.5%
1
+8.6%
1
+10.5%
1
-10.6%
Total debt
1
+0.0%
1
+0.1%
1
+0.0%
1
+4.0%
1
+6.5%
1
+8.6%
1
+10.5%
1
-10.6%
Net cash
138
+460.3%
106
+285.9%
71
+449.4%
44
+113.7%
25
+190.5%
28
+56.3%
13
+693.4%
20
+515.2%
Ratios
Current ratio
18.83x
17.22x
10.72x
8.28x
4.91x
4.64x
1.72x
2.26x
Debt to equity
0.01x
0.01x
0.01x
0.01x
0.03x
0.03x
0.11x
0.04x
Return on equity
-23.58%
-27.42%
-37.90%
-56.85%
-100.42%
-97.73%
-326.27%
-203.12%
Return on assets
-22.33%
-25.80%
-34.29%
-50.32%
-81.28%
-77.61%
-158.92%
-121.79%
Book value per share
0.68
0.59
0.46
0.36
0.26
0.31
0.13
0.25
How these figures are calculated

Quarterly columns are single-quarter amounts. When a 10-Q reports only a year-to-date total, as cash flow statements do, the quarter is that total minus the previous quarter's year-to-date total. The fourth quarter is the annual report's full year minus the first nine months. A column marked YTD is a year-to-date total, shown when the earlier report needed for the single quarter is missing. USD in millions, except ratios and per-share amounts. Cash and investments adds short-term and long-term marketable securities to cash. Debt due within a year is the borrowings that are not already in long-term debt. Total debt is those borrowings plus lease liabilities. Net cash is cash and investments minus total debt. Return on equity and return on assets divide the trailing twelve months of net income by the balance on that date. Debt to EBITDA uses the trailing twelve months of EBITDA. More on our methodology.

Company profile

Industry
Pharmaceutical Preparations (SIC 2834)
Listed as
SLS (Nasdaq)
Fiscal year ends
December 31
Incorporated in
DE
Headquarters
New York, NY
SEC filer status
Non-accelerated filer, Smaller reporting company
SEC CIK
1390478
Former names
GALENA BIOPHARMA, INC. (until Dec 15, 2017); Galena Biopharma, Inc. (until Dec 15, 2017); RXI PHARMACEUTICALS CORP (until Sep 21, 2011)

Other Pharmaceutical Preparations companies

All 570 Pharmaceutical Preparations companies

Source: SEC EDGAR filings. This is company-reported data, not investment advice.